Lapatinib-Based Therapy in Heavily Pretreated HER2-Positive Metastatic Breast Cancer: A Single Institution Experience

Eccles S.A. : The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mamm Gland Biol Neoplasia, 6: 393–406, 2001.

Graus-Porta D. , Beerli R.R. , Daly J.M. , Hynes N.E. : ErbB-2, the preferred heterodimization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO J, 16: 1647–1655, 1997.

Slamon D.J. , Clark G.M. , Wong S.G. , Levin W.J. , Ullrich A. , McGuire W.L. : Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235: 177–182, 1987.

Wolff A.C. , Hammond E.H. , Hayes D.F. , Schwartz J.N. : American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth receptor 2 testing in breast cancer. J Clin Oncol, 25: 118–145, 2007.

Slamon D.J. , Leyland-Jones B. , Shak S. , Fuchs H. , Paton V. , Bajamonde A. , Fleming T. , Eiermann W. , Wolter J. , Pegram M. , Baselga J. , Norton L. : Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344: 783–792, 2001.

Marty M. , Cognetti F. , Maraninchi D. , Snyder R. , Mauriac L. , Tubiana-Hulin M. , Chan S. , Grimes D. , Antón A. , Lluch A. , Kennedy J. , O'Byrne K. , Conte P. , Green M. , Ward C. , Mayne K. , Extra J.M. : Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 Study Group. J Clin Oncol, 23: 4265–4274, 2005.

Dawood S. , Broglio K. , Buzdar A.U. , Hortobagyi G.N. , Giordano S.H. : Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol, 28: 92–98. 2010.

von Minckwitz G. , du Bois A. , Schmidt M. , Maass N. , Cufer T. , de Jongh F.E. , Maartense E. , Zielinski C. , Kaufmann M. , Bauer W. , Baumann K.H. , Clemens M.R. , Duerr R. , Uleer C. , Andersson M. , Stein R.C. , Nekljudova V. , Loibl S. : Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03–05 study. J Clin Oncol, 27: 1999–2006, 2009.

Geyer C.E. , Forster J. , Lindquist D. , Chan S. , Romieu C.G. , Pienkowski T. , Jagiello-Gruszfeld A. , Crown J. , Chan A. , Kaufman B. , Skarlos D. , Campone M. , Davidson N. , Berger M. , Oliva C. , Rubin S.D. , Stein S. , Cameron D. : Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355: 2733–2743, 2006.

Cameron D. , Casey M. , Press M. , Lindquist D. , Pienkowski T. , Romieu C.G. , Chan S. , Jagiello-Gruszfeld A. , Kaufman B. , Crown J. , Chan A. , Campone M. , Viens P. , Davidson N. , Gorbounova V. , Raats J.I. , Skarlos D. , Newstat B. , Roychowdhury D. , Paoletti P. , Oliva C. , Rubin S. , Stein S. , Geyer C.E. : A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat, 112: 533–543, 2008.

Scaltriti M. , Verma C. , Guzman M. , Jimenez J. , Parra J.L. , Pedersen K. , Smith D.J. , Landolfi S. , Ramon Y , Cajal S. , Arribas J. , Baselga : Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene, 28: 803–814, 2009.

Spazzapan S. , Crivellari D. , Tumolo S. , Lombardi D. , Magri M.D. , Russo A.E. , Scalone S. , Talamini R. , Miolo G. , Veronesi A. : Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2 positive metastatic breast cancer: A monoinstitutional experience. J Clin Oncol, 28: 15s (suppl; abstr 1082), 2010.

Capri G. , Chang J. , Chen S-C , Conte P. , Cwiertka K. , Jerusalem G. , Jiang Z. , Johnston S. , Kaufman B. , Link J. , Ro J. , Schütte J. , Oliva C. , Parikh R. , Preston A. , Rosenlund J. , Selzer M. , Zembryki D. , De Placido S. : An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol, 21: 474–480, 2010.

Maroun J.A. , Anthony L.B. , Blais N. , Burkes R. , Dowden S.D. , Dranitsaris G. , Samson B. , Shah A. , Thirlwell M.P. , Vincent M.D. , Wong R. : Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol, 14: 13–20, 2007.

Benson AB 3rd , Ajani J.A. , Catalano R.B. , Engelking C. , Kornblau S.M. , Martenson J.A. Jr. , McCallum R. , Mitchell E.P. , O'Dorisio T.M. , Vokes E.E. , Wadler S. : Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol, 22: 2918–2926, 2004.

Therasse P. , Arbuck S.G. , Eisenhauer E.A. , Wanders J. , Kaplan R.S. , Rubinstein L. , Verweij J. , Van Glabbeke M. , van Oosterom A.T. , Christian M.C. , Gwyther S.G. : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92: 205–216, 2000.

Huang Z. , Brdlik C. , Jin Pet , Shepard H.M. : A pan-HER approach for cancer therapy: background, current status and future development. Expert Opin Biol Ther, 9: 97–110, 2009.

Finn R.S. , Press M.F. , Dering J. , Arbushites M. , Koehler M. , Oliva C. , Williams L.S. , Di Leo A. : Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER-2 negative or unknown metastatic breast cancer. J Clin Oncol, 27: 3908–3915, 2009.

Di Leo A. , Gomez H.L. , Aziz Z. , Zvirbule Z. , Bines J. , Arbushites M.C. , Guerrera S.F. , Koehler M. , Oliva C. , Stein S.H. , Williams L.S. , Dering J. , Finn R.S. , Press M.F. : Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol, 26: 5544–5552, 2008.

Johnston S. , Pippen J. Jr. , Pivot X. , Lichinitser M. , Sadeghi S. , Dieras V. , Gomez H.L. , Romieu G. , Manikhas A. , Kennedy M.J. , Press M.F. , Maltzman J. , Florance A. , O'Rourke L. , Oliva C. , Stein S. , Pegram M. : Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for post-menopausal hormone receptor-positive metastatic breast Cancer. J Clin Oncol, 27: 5538–5546, 2009.

Crown J.P. , Burris H.A. , Boyle F. , Jones S. , Koehler M. , Newstat B.O. , Parikh R. , Oliva C. , Preston A. , Byrne J. , Chan S. : Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat, 112: 317–325, 2008.

Crown J.P. , Burris H.A. , Jones S. : Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC). J Clin Oncol, 25: 38s, (suppl; abstract 1027), 2007.

Jones S.F. , Burris HA 3rd , Yardley D.A. : Lapatinib (an oral dual kinase inhibitor) plus weekly or every 3 week paclitaxel. 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, December 8–11 (abstr 1069), 2004.

Perez E.A. , Koehler M. , Byrne J. , Preston A.J. , Rappold E. , Ewer M.S. : Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc, 83: 679–686, 2008.

Crivellari D. , Spazzapan S. , Magri M.D. , Frustaci S. , Talamini R. , Scalone S. , Torrisi E. , Lombardi D. , Miolo G. , Veronesi A. : Lapatinib plus capecitabine in highly pretreated HER2-positive metastatic breast cancer: A single-institution experience. J Clin Oncol, 28: 15s, (suppl; abstr 1145), 2010.